MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TRANSENDOCARDIAL INJECTION OF IXMYELOCEL-T IN SUBJECTS WITH HEART FAILURE DUE TO ISCHEMIC DILATED CARDIOMYOPATHY (IDCM).
Phoenix/Scottsdale, Ariz., Jacksonville, Fla., Rochester, Minn.
Open for Enrollment
Why is this study being done?
The primary objective of this study is to evaluate the efficacy of ixmyelocel-T compared to placebo (vehicle control) on the average per patient number of all-cause deaths, cardiovascular hospital admissions, and unplanned outpatient or emergency department visits to treat acute decompensated heart failure, over the 12 months following administration of investigational product (IP).
Who can I contact for additional information about this study?
Rochester: Beth Kaping, RN 507-255-7962
Sarah Shonyo 507-255-2648
Scottsdale: Barbara Knight 480-342-2545
Jacksonville: Estela Staggs 904-953-8509